DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the LUPIN LIMITED (LUPIN) share price today?

LUPIN LIMITED (LUPIN) is trading at ₹2,443.2 on the NSE, down 2.29% on the day. Source: DocStoX.

What is the PE ratio of LUPIN LIMITED?

LUPIN LIMITED has a price-to-earnings (PE) ratio of 20.9 in the Healthcare sector.

What is the market capitalisation of LUPIN LIMITED?

LUPIN LIMITED has a market capitalisation of approximately ₹1,11,704 crore.

LUPIN LIMITED

F&O

LUPIN·NSE·Healthcare

₹2,443.20▼ -57.30 (-2.29%)

Healthcare · Pharmaceuticals

High-quality returns — 29% on equity

NIFTY 200NIFTY 500NIFTY MIDCAP 150

Day₹2428.00

₹2489.60

52W₹1837

₹253088%

Open

₹2480.70

High

₹2489.60

Low

₹2428.00

Prev Close

₹2500.50

Volume

6.78L

VWAP

₹2444.93

Snapshot

Key fundamentals

Market Cap

₹1.12L Cr

P/E Ratio

20.94Fair

P/B Ratio

4.89

EPS

₹116.65

Book Value

₹491.00

ROE

29.10%Strong

ROCE

30.00%Efficient

Dividend Yield

0.72%

Debt / Equity

0.29Low

Face Value

₹2.00

52W High

₹2529.50

52W Low

₹1836.80

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatMedium uncertainty

Fair value estimate

₹1,028

▼ 57.9%downside

Trading at ₹2,443 — 58% above our estimate

BearFair valueBull

₹874₹1,028₹1,182

/100

Business quality — High quality

Growth 88Profitability 98Efficiency 50Valuation 79

Plain English

Our view

High-quality returns — 29% on equity
Low debt relative to equity
Fundamental red flags (Piotroski 1/9)

Strengths

Low debt relative to equity
Strong returns on equity (29%)
Capital is working hard (ROCE 30%)
Revenue compounding 19% over 3 years

Risks

Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

29% ROE fading to 12% over ~10 yrs, on ₹491 book

₹998

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹1,135

Analyst target

No analyst coverage

—

Blended fair value₹1,028

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Strong returns on equity (29%)
Capital is working hard (ROCE 30%)
Revenue compounding 19% over 3 years
Profit growing 129% a year

Bear case

Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

20.9Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

29.1%Strong

Above 15% is considered healthy for Indian equities

ROCE

30.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.29Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹1.12L Cr

P/B

4.89

EPS

₹116.65

Div Yield

0.72%

What changed

Recent changes

Foreign investors+0.2% stake last quarter
Domestic institutions-0.3% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 20.9×

Growth

Strong

+19% rev CAGR

Profitability

Excellent

29.1% ROE

Financial health

Rock solid

D/E 0.29

Momentum

N/A

No technicals

Today

Trading activity

Delivery %62.0%

Turnover₹16586.75L Cr

Trades33,919

VWAP₹2444.93

Face value₹2.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+18.9%

+13.0%

10Y

+7.0%

Profit

+128.6%

+34.3%

10Y

+9.0%

EPS

+131.1%

+34.2%

10Y

+8.8%

Profile

Pros

Company has delivered good profit growth of 37.4% CAGR over last 5 years
Company has been maintaining a healthy dividend payout of 17.1%

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors bought 0.22 pts; domestic institutions reduced 0.26 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

47%

Promoter

Promoters

46.9%-0.03

Public

5.0%-0.05

FII / FPI

21.7%+0.22

DII

25.3%-0.26

Others

1.1%

Total shareholders

2,90,411+1,480 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter46.86%

FII21.71%

DII25.32%

Public5.05%

Others1.06%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

F&O

LUPIN LIMITED valuation & research

Deep-dive tools with DocStoX's fair-value estimate, ratios and peers.

Fair Value Intrinsic Value DCF Valuation Financial Ratios Peers

LUPIN LIMITED peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

SUN PHARMACEUTICAL IND L DIVI S LABORATORIES LTD TORRENT PHARMACEUTICALS L APOLLO HOSPITALS ENTER. L ZYDUS LIFESCIENCES LTD CIPLA LTD MAX HEALTHCARE INS LTD MANKIND PHARMA LIMITED DR. REDDY S LABORATORIES AUROBINDO PHARMA LTD LAURUS LABS LIMITED FORTIS HEALTHCARE LTD

Compare LUPIN LIMITED with peers

LUPIN LIMITED vs SUN PHARMACEUTICAL IND L LUPIN LIMITED vs DIVI S LABORATORIES LTD LUPIN LIMITED vs TORRENT PHARMACEUTICALS L LUPIN LIMITED vs APOLLO HOSPITALS ENTER. L LUPIN LIMITED vs ZYDUS LIFESCIENCES LTD LUPIN LIMITED vs CIPLA LTD

LUPIN LIMITED

Key fundamentals

Key statistics

Recent changes

News impact

Overview

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership breakdown

Ownership over time

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Frequently asked questions

F&O

LUPIN LIMITED valuation & research

LUPIN LIMITED peers in Healthcare

Compare LUPIN LIMITED with peers

Key statistics

Recent changes

News impact

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Ownership breakdown

Ownership over time

Frequently asked questions